Molecular mechanisms of probiotic prevention of antibiotic-associated diarrhea
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2020Journal
Current Opinion in BiotechnologyPublisher
Elsevier LtdType
Article
Metadata
Show full item recordAbstract
Antibiotic-associated diarrhea (AAD) is a common and unintended adverse effect of antibiotic treatment. It is characterized by the disruption of the gut microbiota, decreased intestinal short chain fatty acid (SCFA) concentrations, accumulation of luminal carbohydrates and colonic bile acids, altered water absorption, and ultimately diarrhea. Probiotics were shown to prevent AAD in numerous clinical trials. This review examines what is currently known about how probiotics reduce the risk for AAD via modulating the gut microbiota, altering nutrient and bile acid metabolism, inducing epithelial solute transporter activity, supporting intestinal barrier function, and influencing the immune system. Although probiotics are frequently prescribed with antibiotic use, mechanistic evidence verifying how they confer protection against AAD is extremely limited. This information is urgently needed for improving recommendations for sustaining probiotic development and for implementing probiotics in clinical settings.Sponsors
This work was supported by awards from the National Institutes of Health , National Institute of Child and Human Development ( 1R01HD088428-01A1 ) and Office of Dietary Supplements ( 3R01HD088428-02S1 ).Keyword
antibiotic associated diarrheaDiarrhea--prevention & control
Probiotics
Gastrointestinal Microbiome
Bile Acids and Salts
Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85079557092&doi=10.1016%2fj.copbio.2020.01.005&partnerID=40&md5=b5b85ec757d93ddc68523f1bef7abcd7; http://hdl.handle.net/10713/12131ae974a485f413a2113503eed53cd6c53
10.1016/j.copbio.2020.01.005